This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/08/12

    Positive results for Humira (Abbott) for pediatric patients with Crohn's Disease

    Humira (adalimumab), from Abbott, is effective in maintaining remission in pediatric patients with Crohn's disease, according to a new study...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    17/02/13

    Positive data from Phase III study of Humira (AbbVie) in pediatric patients with Crohn's Disease

    New data from the Phase III IMAgINE-1 trial of Humira (adalimumab), from AbbVie, shows that pediatric Crohn's Disease patients taking...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/10/12

    CHMP recommends Humira (Abbott) for paediatric patients with Crohn's Disease

    The CHMP has adopted a positive opinion for Humira (adalimumab), from Abbott Labs, for the treatment of paediatric patients aged...

    Journals
    Journal
    08/02/19

    Adalimumab Effectiveness Up to Six Years in Adalimumab-naive Patients with Crohn's Disease: Results of the PYRAMID Registry

    Background: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira ®), as used in routine clinical practice.

    • Source: Inflammatory Bowel Diseases
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    04/04/16

    EU's CHMP recommends approval of Humira (adalimumab) for Crohns disease in paediatric patients- AbbVie

    The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    27/08/17

    European Commission approves Imraldi, a biosimilar referencing Humira (adalimumab) to treat the originator drug indications- Biogen.

    Samsung Bioepis Co., Ltd. announced the European Commission’s (EC) approval of Imraldi, a biosimilar referencing Humira (adalimumab), for the treatment...

    Ulcerative Colitis
    Inflammatory Bowel Disease Learning Zone
    13/10/21

    Understanding Crohn’s disease

    What is Crohn’s disease and how does it affect patients?

    • Sponsored content
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    25/03/17

    EU Commission approves Amgevita (biosimilar adalimumab) for all indications of the originator drug.- Amgen.

    Amgen has announced that the European Commission (EC) has granted marketing authorization for Amgevita (biosimilar adalimumab) in all available indications....

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    EU CHMP recommends approval of Amgevita (adalimumab biosimilar) for rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis and uveiti-Amge

    The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Amgevita (adalimumab biosimilar), from Amgen, intended for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and uveitis.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    25/09/14

    FDA approves Humira for Crohns in patients 6 years and older - AbbVie

    The FDA has approved Humira (adalimumab), from AbbVie, for reducing signs and symptoms, and achieving and maintaining clinical remission, in...

    See more